In the BESIDE study, combination therapy (antimuscarinic [solifenacin] and β 3 -adrenoceptor agonist [mirabegron]) improved efficacy over solifenacin monotherapy without exacerbating anticholinergic side effects in overactive bladder (OAB) patients; however, a potential synergistic effect on the cardiovascular (CV) system requires investigation.
| INTRODUCTION
The symptom complex of overactive bladder (OAB) is defined as urinary urgency, often accompanied by increased daytime micturition frequency and nocturia in the absence of urinary tract infection or other obvious pathology; urgency incontinence may or may not be present. 1, 2 OAB is estimated to affect 20% of the global population by 2018. 3 Increasing age is the most common risk factor for OAB, with current prevalence rates of 30%-40% in patients aged ≥65 years.
4,5
Males and females are equally affected, however, certain symptoms predominate in males (urgency and nocturia) and females (incontinence). 6, 7 Since OAB is an age-related condition, significantly more patients present with concomitant cardiovascular (CV) comorbidities (eg, hypertension) compared with non-OAB patients, 8 which emphasises the importance of evaluating the CV safety of OAB pharmacotherapies.
The two available oral pharmacotherapies-antimuscarinics and the β 3 -adrenoceptor agonist, mirabegron-mediate relaxation of the bladder by antagonism of the muscarinic M 2 and M 3 receptor subtypes, 9 or stimulation of the β 3 -adrenoceptor subtype, in the urothelium and detrusor muscle. 10 Muscarinic (M 2 , M 3 ) receptors and β-adrenoceptors (β 1 , β 2 and β 3 ) are also expressed in the CV system.
The M 2 receptor has a functional role in mediating heart rate 11 and the M 3 receptor mediates vasodilation, 12 and their antagonism could potentially increase blood pressure or heart rate, prolong the QT interval and induce polymorphic ventricular tachycardia (torsade de pointes). 11 The β 1 -adrenoceptor mediates increased heart rate and force of contraction and the β 2 -adrenoceptor mediates vasodilation in the vascular smooth muscle. 13 The role of the β 3 -adrenoceptor is less clear in human physiology, however, in vitro, the activation of the β 3 -adrenoceptor induces positive inotropic effects in human atrial tissue and negative inotropic effects in ventricular tissue. 14 The antimuscarinic, solifenacin, is selective for the M 3 subtype, 15 while in-vitro studies show that mirabegron has a 150-fold and 33-fold higher affinity for the β 3 -vs. β 1 -and β 2 -adrenoceptor subtypes. 16 Given the location of the M 3 receptor and β 3 adrenoceptor in CV tissues, and the high density of β 1 adrenoceptors in the heart, potential effects on the heart and vasculature cannot be excluded when these drugs are used as monotherapy or in combination.
Mirabegron and solifenacin share similar efficacy in the treatment of OAB, 17 and are considered to have an acceptable CV safety profile at therapeutic doses. 18, 19 As per mirabegron's labelling, periodic blood pressure monitoring is advocated during treatment, and mirabegron is not recommended in patients with severe uncontrolled hypertension (systolic blood pressure [SBP] ≥180 mm Hg and/or diastolic blood pressure [DBP] ≥110 mm Hg). 20 Given the lack of antimuscarinic and mirabegron data in older patients with significant CV risk factors in Phase III trials, it is considered good clinical practice to periodically monitor blood pressure and heart rate in OAB patients aged >80 years. 18, 19 OAB patients are usually initiated on an antimuscarinic, however, persistence is often poor because of bothersome anticholinergic side effects (eg, blurred vision, dry mouth) or inadequate improvement in symptoms. 21, 22 Switching to an alternative antimuscarinic usually has little impact in terms of improved persistence, 23 while dose escalation can often exacerbate the anticholinergic burden leading to treatment discontinuation. 21, 24 Several OAB trials investigating combinations of solifenacin (2.5/5/10 mg) and mirabegron (25/50 mg) have demonstrated an additive benefit in efficacy without compromising safety vs. solifenacin monotherapy. [25] [26] [27] In the BESIDE study (NCT01908829), adding mirabegron 50 mg to solifenacin 5 mg further improved OAB symptoms and patient-reported outcomes vs. solifenacin 5 mg or 10 mg, and was welltolerated in OAB patients remaining incontinent after initial solifenacin 5 mg. 25, 28 Herein, we report on the CV safety outcomes from BESIDE including subpopulations stratified by hypertensive status and gender (age-related CV safety will be reported in a subsequent manuscript).
| METHODS

| Study design and participants
The methodology for BESIDE has been previously described. 25 In summary, adults with OAB symptoms for ≥3 months entered a 2-week screening/wash-out period, followed by a run-in period with singleblind daily solifenacin 5 mg for 4 weeks provided they reported an average of ≥2 incontinence episodes/24 h prior to the run-in period.
Patients remaining incontinent at baseline (≥1 episode during the 3-day bladder diary), who satisfied inclusion, and did not meet exclusion criteria, were randomised 1:1:1-12 weeks of daily double-blind treatment with combination (solifenacin 5 mg/mirabegron 25 mg, increasing to 50 mg after week 4), solifenacin 5 mg or 10 mg monotherapy.
What's known
• A combination of antimuscarinic (solifenacin 5 mg) and β 3 -adrenoceptor agonist (mirabegron 50 mg) improves efficacy without exacerbating anticholinergic side effects vs. solifenacin monotherapy (5 mg, 10 mg) in the treatment of overactive bladder (OAB).
• Cardiovascular (CV) comorbidities are more prevalent in OAB patients compared with the non-OAB population.
• Mirabegron and solifenacin in combination may potentially affect the CV system; however, monotherapy use at therapeutic doses indicates no CV safety concerns.
What's new
• Using a combination of mirabegron and solifenacin does not have a synergistic effect on the CV system since the frequency of CV-related treatment-emergent adverse events, change in vital signs and ECG parameters are comparable with solifenacin monotherapy (5 mg and 10 mg).
| CV safety assessment
The frequency of CV-related treatment-emergent adverse events (TEAEs) was assessed during the study and 2-week follow-up and included increased blood pressure, QT prolongation, increased heart rate, tachycardia, atrial fibrillation, and palpitations. The mean values and change from baseline at EoT in the PR interval, RR interval, QRS interval, QT interval corrected by Fridericia's formula (QTcF), and heart rate are reported in the overall population. The frequency of QTcF extreme values (>450 mseconds, >480 mseconds and >500 mseconds) and extremes in change from baseline (>30 mseconds and >60 mseconds) were reported during double-blind treatment in the overall population and stratified by gender. For the interpretation of the ECGs by the central reader, the percentage of patients who had "no categorical change", "abnormal to normal" and "normal to abnormal" during double-blind treatment were presented.
| Statistical analysis
Sample size calculations related to categorical changes in the primary efficacy endpoint (incontinence episodes/24 h), were based on previous studies with mirabegron alone and in combination with solifenacin, and are described in the primary analysis of BESIDE. 25 The safety analysis set (SAF) consisted of all randomised patients who received ≥1 dose of double-blind treatment and was used for the analysis of CV safety variables.
CV TEAEs of interest (increased blood pressure; QT prolongation; increased heart rate, tachycardia, atrial fibrillation and palpitations) were identified using standardised MedRA queries (v16.0).
The percentage of patients who reported ≥1 AE were summarised by System Organ Class and Preferred Term by treatment with corresponding 95% CI. Tachycardia was reported as a TEAE according to the investigator's judgement independent of a pulse rate ≥100 bpm.
Tachycardia was also reported according to the standardised assessment of vital sign data based on a mean pulse rate ≥100 bpm. Additional sensitivity analyses were performed including antihypertensive use at screening or a different age group factor (<45, ≥45
to <65, ≥65 years) in the ANCOVA model to analyse changes from baseline in vital signs.
Heart rate, PR interval, RR interval, QRS interval and QTcF were summarised descriptively for each treatment group at each visit including changes from baseline to each postbaseline visit. The worst non-missing value was used in the analysis for categorical ECG variables reported by the central reader.
| RESULTS
| Patient demographics and baseline characteristics
Overall, 2174 patients were randomised into the study, of which 2172 (99.9%) received double-blind study drug and were included in the safety analysis set (SAF). The discontinuation rate (post-randomisation) was low (6.2%) with no relevant differences among treatment groups. The overall mean age at screening was 57.5 years. Approximately 37% of patients had a history of hypertension and approximately 7.5% and 4.5%, respectively, had type 1 and type 2 diabetes mellitus in each treatment group at baseline ( Table 1 ). The most frequently reported concomitant medications during treatment were agents acting on the renin-angiotensin system (~27%); medication use was comparable across treatment groups (Table 1) .
| CV-related TEAEs
Overall, the frequency of TEAEs of interest related to the CV system (increased blood pressure; QT prolongation; increased heart rate, tachycardia, atrial fibrillation and palpitations) was low (<2.0%) and comparable across treatment groups. Hypertension as a TEAE was one APTC/MACE CV event (non-fatal myocardial infarction) in the solifenacin 10 mg group. In addition, there was one event in the solifenacin 10 mg group for which there was insufficient data to adjudicate, and three events in the combination group were adjudicated as non-CV events.
| Vital signs
In the overall SAF population, the adjusted mean ( There were no notable differences between combination and solifenacin monotherapies in vital signs in subpopulations stratified by hypertensive status and β-blocker use, in the sensitivity analyses using a different age group factor or hypertensive medication use at screening in the model (Figure 1) , and between male and female patients (Table 3) .
The percentage of patients with increases in vital signs at EoT that met the change from baseline criteria at three consecutive visits was low and similar across treatment groups in the overall population (Figure 2A-C) . Similar findings were evident in the subpopulations according to hypertension history, hypertensive status at screening and β-blocker use, with the exception of pulse rate in the past history of hypertension cohort (n=53) in which no more than 3/17 (17.6%) patients receiving combination met one of the three criteria for change from baseline vs. none in the solifenacin groups (Table 4) .
At EoT, a similar proportion of patients (~80%) in each treatment group had no shift in vital sign severity, while less than 10% of patients in each group experienced a categorical increase ( The frequency of tachycardia, according to the standardised assessment of vital sign data, and defined as an average pulse rate ≥100 bpm, was low and similar across groups during the treatment period (combination n=8, 1.1%; solifenacin 5 mg n=12, 1.7% and solifenacin 10 mg n=10, 1.4%).
T A B L E 1 Patient demographics and CV-related baseline characteristics (SAF)
Combination n=725
Solifenacin 5 mg n=728
Solifenacin 10 mg n=719
Sex, n (%) 
| ECG results
Mean changes from baseline to EoT in ECG parameters (PR, RR, QRS, QTcF and heart rate) were generally similar across treatment groups; the most notable exception being the QTcF, which was higher in the solifenacin 10 mg (3.30 mseconds) group vs. combination (0.49 mseconds) and solifenacin 5 mg (0.77 mseconds) ( Table 5 ).
The percentage of patients with a normal (~72%-75%) and abnor- 
| DISCUSSION
CV safety concerns are particularly relevant in chronic medical conditions such as OAB, in which patients have a significantly higher rate of pre-existing CV comorbidities than patients without OAB. The frequency of CV TEAEs and the magnitude of change in vital signs and ECG parameters with combination therapy is consistent with mirabegron and solifenacin monotherapy, 18, 19 and with other studies that have investigated a combination of mirabegron and solifenacin in a Japanese OAB population 26 and in a Phase II dose-ranging study. 27 The frequency of hypertension (<2%) across treatment groups in BESIDE is considerably lower than that reported with placebo and mirabegron monotherapy in previous 12-week Phase III studies (placebo n=7.6%, mirabegron 50 mg n=7.5%). 29 However, hypertension was defined using three prespecified criteria in the previous Phase III monotherapy trials, whereas in BESIDE there were no predefined criteria and hypertension was reported as an AE, if considered clinically relevant by the investigator. Similarly, the overall frequency of 
T A B L E 1 (Continued)
T A B L E 2 Treatment-emergent adverse events (TEAEs) (MedRA v16.0) of interest related to the CV system, serious CV-related TEAEs and frequency of adjudicated CV-related TEAEs (SAF) APTC, antiplatelet trialists collaboration; CV, cardiovascular; ECG, electrocardiogram; MACE, major adverse cardiovascular event; PT, preferred term; SOC, system organ class; TEAEs, treatment-emergent adverse events. TEAE refers to an AE which started or worsened in the period from first double-blind medication intake until 30 days after the last double-blind medication intake. a One patient experienced both tachycardia and palpitations; the patient is counted once under each of palpitations and tachycardia, but only once under the SOC cardiac disorders.
T A B L E 2 (Continued)
F I G U R E 1 Adjusted change from baseline to EoT for vital signs in the overall population and by sensitivity analyses: A, systolic blood pressure: combination vs. solifenacin 5 mg and 10 mg; B, diastolic blood pressure: combination vs. solifenacin 5 mg and 10 mg; C, Pulse rate: combination vs. solifenacin 5 mg and 10 mg tachycardia (reported as a TEAE by the investigator or a mean pulse rate ≥100 bpm) with combination therapy (1.4%) was lower than that reported with mirabegron 50 mg monotherapy in the previous 12-week studies (3.8%).
29
The frequency of CV TEAEs reported in BESIDE compares favourably with the rate of CV events reported in the general population.
In the Framingham study, after 30 years of follow-up, the frequency of hypertension (SBP ≥160 mm Hg and DBP ≥95 mm Hg) increased with age in men from 3.3% at ages 30-39 to 6.2% at ages 70-79, and in women from 1.5% at ages 30-39 to 8.6% at ages 70-79. 30 The frequency of tachycardia (≥100 bpm) in the general US population based on national reference data on resting pulse rate is 1.3% in men and 1.9% in women. Adjusted change from baseline values and 95% CIs are generated from ANCOVA model with treatment group, gender, age group, 4-week incontinence reduction group, geographic region and interaction between age group (<65, ≥65 years) and treatment group as fixed factors and baseline as a covariate. Differences of adjusted means are calculated by subtracting adjusted mean of solifenacin treatment from adjusted mean of combination treatment.
A substantial proportion of the BESIDE population was taking medication to control hypertension, which may have concealed potential increases in blood pressure; however, this would apply across all treatment arms. Furthermore, the study lacked a placebo arm, which would have allowed a more robust comparison of CV safety between active treatment and a control cohort in this refractory incontinent population. In this paper, CV safety was not reported in patients stratified by older age (≥65 years and ≥75 years)-the cohort most likely to have pre-existing CV morbidities and at risk of developing CV-related AEs-results for these patients will be presented in a subsequent analysis in older patients from the BESIDE study.
In addition to the safety analysis in older patients in BESIDE, future subanalyses using integrated clinical trial data could investigate combination therapy vs. placebo in other high risk CV populations (eg, diabetes, hypertension, and BMI >30), and compare office-based vs.
ambulatory blood pressure monitoring.
| CONCLUSION
In OAB patients treated with a combination of mirabegron and solifenacin, the frequency of CV-related AEs and changes from baseline in vital signs and ECG parameters were comparable with the recommended doses of solifenacin monotherapy (5 mg and 10 mg), indicating a lack of a synergistic effect on CV safety with combination.
However, good clinical practice advocates regular blood pressure monitoring in older patients where CV risk may be cumulative because of comorbidities or co-medication. In the case that a subject has an SBP value falling into one category and a DBP value falling into another category, the subject will be summarised in the most severe category EoT, end of treatment; QTcF, QT interval corrected using Fridericia's formula. Patients (%)
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